Evaluation of drug resistant tuberculosis prevention and control in Jiangsu,2016-2020
Objective To evaluate the performance of drug-resistant tuberculosis(DR-TB)prevention and control in Jiangsu province from 2016 to 2020,and provide evidence for the further improvement of DR-TB prevention and control policy.Methods A unified field questionnaire was used for the mid-stage evaluation of the investment for the prevention and control of DR-TB,the human resources and laboratory capacity of TB prevention and control institutions and the supply of second-line anti-TB drugs in the TB control program in Jiangsu during the 13th Five-Year Plan period.The data from the TB Information Management System during this period were collected.Results The investment for the prevention and control of DR-TB in Jiangsu increased year by year,from 3.16 million yuan(RMB)in 2016 to 44.96 million yuan(RMB)in 2020.The anti-TB forces in centers for disease control and prevention remained stable,the professionals in designated medical institutions increased and the second-line anti-TB drugs have been included in government centralized procurement list.From 2016 to 2020,the proportion of laboratory confirmed pulmonary TB cases increased from 33.50%to 58.33%(trend x2=12213.323,P<0.001),the drug resistance screening rate in laboratory confirmed TB cases increased from 49.70%to 97.70%(trend x2=12213.323,P<0.001),the average time for DR-TB diagnosis dropped from 64.75 days to 5.95 days,the treatment rate of rifampicin-resistant TB cases increased from 61.52%to 97.75%,the successful treatment rate of RR-TB increased from 63.86%to 80.84%(trend x2=29.547,P<0.001)Conclusion Achievement has been made in the prevention and control of DR-TB in Jiangsu,reaching the target set the TB control program in the"13th Five-Year Plan"period.which might be attributed to the increased investment,expanded drug resistance screening,application of advanced technology and consistent drug supply.
The 13th Five-Year PlanDrug-resistant tuberculosisPerformance effect